BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, May 10, 2026
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

In the clinic for Sept. 28, 2023

Sep. 28, 2023
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Adcentrx, Adverum, Alligator, Alto, Biosenic, Candel, Cantex, Cardiff, Gracell, Kallyope, Remegen, Sensei, Small, Smart Immune, Unity, VBI.
Read More
Infection

Targeting TBK1 and IKKε with synthetic flavonoid reduces COVID-19-like immunopathology in a mouse model

Sep. 26, 2023
TANK-binding kinase 1 (TBK1) serves prominent innate immune functions via complex interactions with adaptor proteins to affect phosphorylation of NF-κB (NF-κB). TBK1 is at the nexus of multiple pathways connecting interferon pathway activation and this is ultimately beneficial or hyperinflammatory-pathological in the context of viral infections.
Read More
Infection

Westvac Biopharma discovers new Mpro inhibitors for SARS-CoV-2

Sep. 22, 2023
Westvac Biopharma Co. Ltd. has described keto amide derivatives acting as 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Read More
Infection

Versitech and Ningbo Combireg Pharmaceutical patent benzothiazole compounds to treat SARS-CoV-2

Sep. 21, 2023
Researchers at Ningbo Combireg Pharmaceutical Technology Co. Ltd. and Versitech Ltd. have described benzothiazole compounds reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Read More

Regulatory actions for Sept. 20, 2023

Sep. 20, 2023
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: 60 Degrees, AB Science, Astex, Atamyo, Beigene, Biophytis, Gilead, GSK, Intelgenx, Merck & Co., Otsuka, Pfizer, Rhythm, Viiv.
Read More

In the clinic for Sept. 20, 2023

Sep. 20, 2023
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Arcturus, Arcutis, Aspargo, Astellas, Avacta, Caliway, Cerevance, Geovax, Immpact, Indaptus, Iveric, Revolution, Saol, Scancell.
Read More

Regulatory actions for Sept. 18, 2023

Sep. 18, 2023
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Almirall, Argenx, Ascendis, Astrazeneca, Daiichi Sankyo, Hemogenyx, Iovance, Merck, Moderna, PTC, UCB, Vertex.
Read More

In the clinic for Sept. 15, 2023

Sep. 15, 2023
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Anavex, Asieris, Biohaven, Coeptis, Edgewise, Scilex, Vincerx.
Read More
Coronavirus variants
Infection

Discovery of a new α-ketoamide derivative as a selective SARS-CoV-2 Mpro inhibitor

Sep. 15, 2023
Novel effective antivirals against SARS-CoV-2 are needed because of the emergence of novel variants and the potential risk of SARS-CoV-2/MERS-CoV recombination. The SARS-CoV-2 main protease (Mpro) is a promising antiviral target. Mpro presents a His41-Cys145 catalytic dyad in the central part of its active site, which confers a natural advantage for developing covalent drugs.
Read More
Infection

Mpro inhibitors described in Medshine Discovery patent

Sep. 14, 2023
Research at Medshine Discovery Inc. has led to the development of 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors potentially useful for the treatment of SARS-CoV-2 infection (COVID-19).
Read More
Previous 1 2 … 29 30 31 32 33 34 35 36 37 … 552 553 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 8, 2026.
  • Rendering of a key measles protein targeted by neutralizing human antibodies

    First measles treatment advances as vaccination rates drop

    BioWorld
    Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
  • Infensa Bioscience identifies new ASIC blockers

    BioWorld Science
    Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
  • Art concept for inflammation in the intestines

    Kymera’s IRF5 degrader shows potential in IBD treatment

    BioWorld Science
    At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
  • Close up of bow of cruise ship

    Hantavirus is ‘sentinel’ more than acute pandemic threat

    BioWorld
    News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing